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Multilocus sequence typing (MLST) was applied to all unique serotype 6C and 6D isolates and a random
selection of serotype 6B and 6A isolates from nasopharyngeal swabs from Fijian children enrolled in a recent
vaccine trial. The results suggest that Fijian serotype 6D has arisen independently from both serotypes 6A/C
and 6B.
Infection with Streptococcus pneumoniae is a leading cause
of death in children worldwide (15, 19, 25). S. pneumoniae
comprises 48 capsular serogroups containing more than 90 sero-
types. Serogroup 6 classically consisted of serotypes 6A and 6B.
The 7-valent conjugate vaccine (Prevnar; PCV7) includes the 6B
antigen and confers some cross-protection against serotype 6A
but not 6C (20, 22). Serotype 6C is important in carriage and
invasive disease, and its prevalence has increased following wide-
spread use of PCV7 (4, 5, 9, 10, 14, 16, 24).
The existence of serotype 6D has been postulated (8) and
was created experimentally (2), but naturally occurring isolates
have not been identified (2, 8, 17) until recently, when we
identified 14 naturally occurring serotype 6D isolates from
nasopharyngeal swabs from Fijian children (11). Recently, two
serotype 6D isolates have been found in Korean children (1).
Initially, serotype 6C was postulated to have arisen from a
single, possibly recent, evolutionary event in which serotype 6A
wciN was replaced by serotype C wciN (21). Subsequent ana-
lyses, predominantly by multilocus sequence typing (MLST),
have shown that 6C is genetically diverse, believed to be a
consequence of multiple separate conversion events or a single
event occurring sufficiently early in pneumococcal evolution (3,
4, 8, 9, 17).
Serotype 6C is usually associated with clonal complexes
(CCs) containing predominantly serotype 6A, and less com-
monly, 6B or non-serogroup-6 serotypes (3, 4, 9, 17). To date,
MLST has been conducted on two serotype 6D isolates from
Korea (ST282) (1), two from China (ST982 and ST4190), and
one from Australia (ST4241) (http://spneumoniae.mlst.net).
However, the molecular epidemiology of serotype 6D isolates
is otherwise uncharacterized.
In this study, we conducted MLST of serogroup 6 isolates to
determine the genetic diversity and likely evolutionary origin
of serotype 6C and 6D isolates.
S. pneumoniae was isolated and identified as described else-
where (18) from children aged 6 to 18 months participating in
the Fiji Pneumococcal Project (FiPP) who had received 0, 1, 2,
or 3 doses of PCV7 and 0 or 1 dose of 23-valent pneumococcal
polysaccharide vaccine (PPV23) (23). Isolates were serotyped
by a multiplex PCR-based reverse line blot (mPCR/RLB) assay
and/or quellung reaction (before factor serum 6d was avail-
able), plus serogroup 6 serotype-specific PCR as previously
described (11, 12).
MLST was applied to all unique serotype 6C and 6D strains
from the FiPP study (n  52 and 24, respectively), of which 24
and 14 isolates, respectively, were included in our previous
report (without ST results) (11). For comparison, we per-
formed MLST on a subset of randomly selected serotype 6A
(n  16) and 6B (n  17) isolates from the FiPP study.
Fresh 18- to 24-h subcultures of S. pneumoniae isolates were
suspended in nuclease-free water (Ambion), and genomic
DNA was extracted using the DNeasy blood and tissue kit
(Qiagen) per the manufacturer’s instructions. MLST was
performed using primer pairs described by the Centers for
Disease Control and Prevention (http://www.cdc.gov/ncidod
/biotech/strep/alt-MLST-primers.htm) (aroE, recP, spi, xpt
and ddl) or Enright and Spratt (6) (gdh and gki), except as
described below.
PCRs were conducted with 25-l volumes containing ap-
proximately 5 ng of genomic DNA, 1 U of AmpliTaq DNA
polymerase (Applied Biosystems), 1  PCR buffer II (50 mM
KCl, 10 mM Tris-HCl [pH 8.3]), 3.0 mM MgCl2, 250 M each
deoxynucleoside triphosphate (dNTP), 0.5 M forward primer,
and 0.5 M reverse primer (Sigma-Aldrich). PCR cycling con-
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ditions were a 5-min hold at 94°C, followed by 35 cycles at 94°C
for 30 s, 60°C for 30 s, and 72°C for 45 s, and a final extension
at 72°C for 5 min. Some isolates which produced no or small
amounts of PCR product from spi (seven 6C and three 6D
isolates) and/or recP (three 6C and one 6A isolate) were suc-
cessfully amplified with primers described by Enright and
Spratt (6) at an annealing temperature of 52°C in 4.5 mM
MgCl2.
Amplicons were sequenced in both directions using capillary
separation on the ABI 3730xl DNA analyzer with ABI BigDye
Terminator labeling (version 3.1) (Australian Genome Re-
search Facility) using the same primers as for amplification.
Contiguous sequences were formed and edited using Se-
quencher 4.9 (Gene Codes Corporation).
Allelic profiles and sequence types (STs) were obtained
and compared to those of other isolates in the MLST data-
base (http://spneumoniae.mlst.net). Relationships between
STs were explored using eBURST version 3 software (Imperial
College, London), which is available at the MLST website. For
this study, a group was defined as two or more isolates which
shared alleles at six of seven loci. Using this stringent defini-
tion, a group also defined a clonal complex (CC). Bootstrap
analyses of the CC founder are also presented where appro-
priate.
Generally, Fijian serogroup 6 isolates were highly clonal,
with the predominant clone in each serotype representing
44% of the isolates. This is not surprising, given that all
strains were isolated from children of similar ages over a rel-
atively short period of time in a small, geographically isolated
area.
Serotype 6A isolates included STs 490 (7/16), 4778, 4779,
499, and 460 (Table 1). ST490 is predicted to be the CC
founder (bootstrap value, 96%) and contains predominantly
serotype 6A isolates in the MLST database. ST4778 and
ST4779 are newly identified in this study and were not assigned
to a CC. The only other ST499 isolate in the database (sero-
type 6A isolate from Finland) was also not assigned to a CC.
ST460 is predicted to be a CC founder (bootstrap value, 88%).
Most serotype 6A isolates (10/16) belonged to STs which con-
tain only serotype 6A in the database (i.e., ST490, ST499, and
ST460).
Serotype 6B isolates had a simple population structure, com-
prising ST176 (15/17) and ST4781 (Table 1). ST176 is pre-
dicted to be the CC founder and contains predominantly 6B
serotypes in the database. ST4781 is a new ST with a new xpt
allele, xpt-325; it clusters with CC176 and is a single-locus
variant (SLV) of ST639.
Serotype 6C isolates included isolates of ST4240 (n  49/
52), ST1715, and ST4780 (Table 1). ST4240 was not assigned
to a CC when the most stringent criterion was used, but when
the stringency was relaxed to define a group as isolates with 5
of 7 shared alleles, it clustered with ST199, which is associated
with multiple serotypes, predominantly 19A. The only other
ST4240 isolate in the database is a serotype 6C isolate from
Australia (26). ST1715 was predicted by eBURST to be a CC
founder, but with a low bootstrap value (23%). The only other
ST1715 isolate in the database is a serotype 6B isolate from
Finland. These results imply evolutionary pathways somewhat
different from those previously reported, mainly in developed
countries, but consistent with the now recognized genetic di-
versity of serotype 6C (3, 4, 8, 9, 17). ST4780 is a newly iden-
tified ST in this study and is not assigned to a CC.
Serotype 6D isolates comprised STs 639 (14/24), 473 (9/24),
and 4240 (Table 1). ST639 is a double-locus variant (DLV) of
ST176, a predicted CC founder (bootstrap value, 71%) com-
prising mainly serotype 6B isolates, including those in this
study. Interestingly, the single Australian serotype 6D isolate
(strain 8649, ST4241) is an SLV of ST176. ST473 is predicted
to be the CC founder (bootstrap value, 100%) and contains
mostly serotype 6A (n  19/25) and a few serotype 6C and 6B
isolates in the database. One serotype 6D isolate belonged to
the ST4240 that was predominant among serotype 6C isolates
TABLE 1. Distribution of STs and eBURST analysis for 109 serotype 6 isolates from Fijian children
Serotype ST No. ofisolates
eBURST analysisa
Serotype(s) shared by ST
in database
(no. of isolates)
Predicted CC founder ST
(bootstrap value %)c
No. of ST (total no.
of isolates) in CC
in databasec
6A 490 7 6A (16) 490 (96) 50 (90)
4778b 3 N/A N/A N/A
4779b 3 N/A N/A N/A
499 2 6A (1) N/A N/A
460 1 6A (14) 460 (88) 64 (94)
6B 176 15 6B (22), 6A (1) 176 (71) 374 (714)
4781b 2 N/A 176 (71) 374 (714)
6C 4240 49 6C (1) N/A N/A
1715 2 6B (1) 1715 (23) 4 (7)
4780b 1 N/A N/A N/A
6D 639 14 6B (1) 176 (71) 374 (714)
473 9 6A (19), 6B (3), 6C (3) 473 (100) 83 (124)
4240 1 6C (1) N/A N/A
a eBURST analyses based on a minimum of six identical loci to define a group or clonal complex (CC).
b New STs identified in this study; ST4781 contains a new xpt allele, xpt-325.
c N/A, STs not assigned to any CC by eBURST.
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in this study. This result was confirmed by repeating the quel-
lung reaction and the MLST and serotype-specific PCR with
new DNA extract.
Together with the small number of other serotype 6D iso-
lates which have been analyzed to date, our results are consis-
tent with the hypothesis that serotype 6D arose mainly from
serotype 6B but had other evolutionary pathways involving
serotype 6A/C and, perhaps, one or more capsule-switching
events. This is also suggested by the single serotype 6D isolates
among 50 ST4240 isolates, which otherwise all belonged to
serotype 6C. We did not identify ST473 among our serotype
6A, 6B, or 6C isolates, which may have provided more infor-
mation about the evolution of ST473 serotype 6D. An impor-
tant caveat to our study is that strains previously identified as
serotype 6A in the MLST database may in fact be serotype 6C;
similarly, strains identified as serotype 6B may be 6D.
Naturally occurring serotype 6D isolates have so far been
reported from Fiji (11; this study), South Korea (1), China, and
Australia (http://spneumoniae.mlst.net) but not among isolates
predominantly from Europe and the United States (2, 8, 17). It
is interesting to speculate whether this predominance in Asia
and Oceania is due to geographical, ethnic, or socioeconomic
factors. In any case, along with the identification of four new
STs and one new allele in our analysis, the importance of
studying pneumococci from a range of geographical areas is
highlighted.
This study is the first comprehensive characterization of the
molecular epidemiology of serotype 6D isolates and of Fijian
pneumococcal isolates in general. Our results suggest that se-
rotype 6D strains may have arisen from both serotype 6A/C
and 6B lineages.
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